Navigation Links
Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
Date:5/15/2013

BOULDER, Colo., May 15, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, MEK162 (licensed to Novartis) and selumetinib (licensed to AstraZeneca) at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4, 2013 in Chicago, Illinois.  Both MEK inhibitors are expected to advance into Phase 3 trials in 2013:  Novartis expects to evaluate MEK162 in NRAS- and BRAF-mutant melanoma and Array expects to evaluate MEK162 in low-grade serous ovarian cancer.  In addition, AstraZeneca expects to begin Phase 3 or pivotal registration trials with selumetinib in non-small cell lung cancer and thyroid cancer. 

The following is a summary of the presentations that will be given at ASCO:  ORAL PRESENTATIONSTitle:Phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma (Abstract # CRA9003)Final results will be presented at ASCO.Presenter: Richard D. Carvajal, MDDate:Saturday, June 1, 2:15-2:30 p.m. CDT (Oral Presentation)Embargo:ASCO's embargo for this abstract will lift on Saturday, June 1 at 6:30 a.m. CDT.Press Conference ASCO will feature this study in the 2013 ASCO Annual Meeting press program on Saturday, June 1 from 8 – 9 a.m. CDT.Title: 

Phase II double-blind, randomized study of selumetinib plus dacarbazine versus placebo plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma (Abstract # 9004)Presenter: Mark R. Middleton, PhD, FRCPDate: 

Saturday, June 1, 2:30-2:45 p.m. CDT POSTER PRESENTATIONSTitle: Preliminary results from a Phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-depe
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
2. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
3. New Versa HD System Tops Elektas Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
4. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
5. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
6. Array BioPharma To Present At The Cowen Annual Health Care Conference
7. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
10. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
11. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Research and Markets  has announced the ... by Application, and by Geography - Global Forecast to ... The medical electronics market is expected to grow at ... the world due to growing income levels, and increasing ... hypertension, and cardiovascular diseases. A growing population coupled with ...
(Date:10/2/2014)... 2, 2014  Eli Lilly and Company (NYSE: ... tabalumab­ -- being studied for the treatment of ... -- due to insufficient efficacy in two pivotal ... on safety concerns. ­­­­ In the ... primary endpoint, at either dose studied, of statistically ...
(Date:10/2/2014)...  InfinityQS International, Inc., the global authority on ... client speakers for Infusion Chicago, its 9 th ... will be held Oct. 9-10, 2014, at the ... from Coloplast, The Kellogg Company, Biomet, General Cable, ... two-day event will also include best practice presentations ...
Breaking Medicine Technology:Medical Electronics (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU) Market - Global Forecast to 2020 2Medical Electronics (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU) Market - Global Forecast to 2020 3Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 2Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies 3InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 2InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 3
... SAN DIEGO, Oct. 4 To mark the beginning ... its breast cancer treatment services at its West Houston ... Emission Mammography) scanners are high-resolution breast PET systems that ... of a lesion.  The metabolic view allows physicians to ...
... ALTOONA, Pa., Oct. 4 In response ... and the importance of "aging-in-place" as an ... Technologies, LLC ("Delta") today announced the introduction ... developed to optimize the homecare therapist. ...
Cached Medicine Technology:SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services 2Delta Health Technologies ClinicalVirtuosoâ„¢ Targets Homecare Therapists 2
(Date:10/2/2014)... Robins & Morton received nine Excellence ... Contractors (ABC) of Alabama. , ABC will recognize ... Sheraton Birmingham Hotel., ,     HealthSouth Rehabilitation ... $25 Million, Obelisk Award (First Place) , ... Million to $25 Million, Obelisk Award (First Place) ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. ... control -- especially long-acting implanted devices -- could slash pregnancy ... new findings suggest. In a study of 1,400 teenage ... the girls, rates of unplanned pregnancy and abortion. Over three ... -- versus a rate of 158 per 1,000 among all ...
(Date:10/2/2014)... 1, 2014 (HealthDay News) -- Children with autism are ... fully capable of being more active, a small study ... of 29 children, some with autism and some without. ... of moderate physical activity and 70 more minutes each ... children with autism scored lower on strength, but had ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... that pull out all the stops to rescue surgical ... but the cost of such heroism is questionable, a ... 5 percent better at saving elderly patients with life-threatening ... with less intensity, said senior author Dr. Amir Ghaferi. ...
(Date:10/1/2014)... strongly associated with Alzheimer,s disease; however, researchers are still ... causal agent of the onset and development of the ... beta-amyloid is not harmful when found in isolation but ... to form the so-called amyloid fibrils , "We are ... with multiple ones because each aggregate of peptide, which ...
Breaking Medicine News(10 mins):Health News:Robins & Morton wins nine awards from Associated Builders and Contractors 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 4Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2
... IntraHealth International will highlight its ... the developing world during the 36th annual ... D.C., May 26-30. Hosted by the Global Health ... = Healthy Communities," focuses on the ways in which ...
... groups, headed by Prof. Nils Brose of the Max Planck ... on behalf of the European Union, to study the role ... the research teams is headed by Prof. Kobi Rosenblum of ... has been awarded a grant of 600,000 Euro. The topic ...
... reports MS medication possession ratio of 86 percent for ... Multiple sclerosis patients managed by a specialty pharmacy program ... risk of being hospitalized for their disease than those ... according to a study completed by HealthCore, Inc.HealthCore researcher ...
... Velocity,s intelligent search capabilities such as geo-spatial search, content ... May 19 Vivisimo ( www.vivisimo.com ), a leading ... that Bupa, an international health and care company with ... selected the Vivisimo Velocity Search Platform ...
... to provide sun protection, laughs and college scholarship ... Today non-profit Cancer for College launches a new ... proceeds from the sunscreen sales will go to ... granting college scholarships to cancer survivors and amputees.To ...
... mice might explain progression from skin to breathing condition ... secreted by eczema-damaged skin might trigger asthma in children, ... study of mice with an eczema-like condition, which suggested ... trigger substance might help prevent asthma. , An estimated ...
Cached Medicine News:Health News:IntraHealth International Addresses Capacity Building and Open Source Technologies at Tech-Themed Global Health Conference 2Health News:MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR 2Health News:MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR 3Health News:Vivisimo Powers Site Search on Bupa's Leading Health Information Websites Worldwide 2Health News:Photos: Will Ferrell Sunscreen to Launch Just in Time for Summer 2Health News:Molecule in Skin May Link Eczema and Asthma 2
... cup system has been designed to enhance ... and cluster hole configurations. The objective of ... on three primary modes: Tilt, migration and ... result in initial and long-term fixation. The ...
Optimal solution for normal acetabulum and younger patients....
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
Medicine Products: